Pulmonary Disease, Chronic Obstructive clinical trials

The registry lists 5,520 studies for Pulmonary Disease, Chronic Obstructive across more than 10 countries. 856 are recruiting or about to start. 4,513 of them are mainly about Pulmonary Disease, Chronic Obstructive (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 2 narrower conditions too, such as Bronchitis, Chronic: 5,589 studies, 861 open.

ClinicalTrials.gov finds 6,474 studies for Pulmonary Disease, Chronic Obstructive. How that becomes 5,520 here

This page counts the studies the registry files under Pulmonary Disease, Chronic Obstructive, and those it files under no condition that list Pulmonary Disease, Chronic Obstructivethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

6,474Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−63Filed under a narrower condition, counted on its own pageBronchitis, Chronic 40 · Pulmonary Emphysema 22
−45List Pulmonary Disease, Chronic Obstructive as a condition, but the registry did not file them under itMost often written as “COPD Exacerbation” (9), “Acute Exacerbation of Chronic Obstructive Pulmonary Disease” (6), and “Asthma-COPD Overlap Syndrome” (4). The registry filed them under other conditions only, most often Respiratory Insufficiency (7) and Pneumonia (5).
−932Match it another way53 name it in the title, 1 in a keyword, and 878 by a synonym or other text the search reads.
5,434Counted here and found by its search93 of them list Pulmonary Disease, Chronic Obstructive in their own words; the registry filed them under no condition.
+86
Counted here, but its search does not find them
The first 20 of 86.
5,520The count on this page

Get an email when these change. Save the Pulmonary Disease, Chronic Obstructive studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 3,415
Status unknown: 666
Recruiting: 555
Terminated: 298
Not yet recruiting: 258
Withdrawn: 141

Phase

Phase 2: 567
Phase 3: 555
Phase 4: 442
Phase 1: 356
Early Phase 1: 34

Where

United States: 1,277
United Kingdom: 620
Germany: 539
France: 405
China: 403
Canada: 397

Who runs them

GlaxoSmithKline (276) · AstraZeneca (240) · Boehringer Ingelheim (236) · Novartis Pharmaceuticals (89) · Chiesi Farmaceutici S.p.A. (61) · Riphah International University (58) · Imperial College London (51) · Assiut University (46)

What is being tested here

Drugs under test in Pulmonary Disease, Chronic Obstructive studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
HSK39004	5	3	6
Fluticasone	3	8	59
GSK573719	3	14	43
Budesonide	3	15	43
Tezepelumab	3	2	4
Lunsekimig	3	3	3
Felcorekibart	3	2	3
Depemokimab	3	3	3
Formoterol	2	40	88
Glycopyrrolate	2	33	73

Drug classes tested here Corticosteroids 8 open · Antimuscarinics 6 open · Bronchodilators 4 open · PDE5 inhibitors 3 open · GLP-1 receptor agonists 2 open

Coming up

49phase 3 studies under way

276studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026Trial to Determine Effective Aspirin Dose in COPD · Phase 3 · Johns Hopkins University
Feb 2027Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease · Phase 3 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Mar 2027Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease · Phase 3 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Jun 2027A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD · Phase 3 · Haisco Pharmaceutical Group Co., Ltd.
Jun 2027A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) · Phase 3 · Hoffmann-La Roche
Sep 2027A Phase 3 Trial of JKN2401 Injection in COPD · Phase 3 · Joincare Pharmaceutical Group Industry Co., Ltd
Sep 2027A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) · Phase 3 · Grifols Therapeutics LLC
Sep 2027A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD · Phase 3 · Haisco Pharmaceutical Group Co., Ltd.
Oct 2027Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease · Phase 3 · Assistance Publique - Hôpitaux de Paris
Nov 2026Self-management Digital Intervention to Promote Physical Activity in People Living With COPD · Institut et Haute Ecole de la Santé la Source

Who these studies take

Of the 555 Pulmonary Disease, Chronic Obstructive studies recruiting now, 305 (55%) set no upper age limit and 82 (15%) stop at 75 or younger. 29 (5%) take children under 18. 1 (<1%) are for women only and 4 (1%) for men only; 87 (16%) take healthy volunteers.

Recruiting studies that take each age, of 555
Age	Women	Men
10	27 (5%)	28 (5%)
18	262 (47%)	263 (47%)
30	300 (54%)	301 (54%)
40	505 (91%)	505 (91%)
50	535 (96%)	538 (97%)
65	535 (96%)	536 (97%)
75	504 (91%)	505 (91%)
85	390 (70%)	391 (70%)

Across all 5,520 studies, recruiting or not: 17% stop at 75 or younger and 6% at 65; 8% take children; <1% are for women only and 3% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Pulmonary Disease, Chronic Obstructive studies take

Of 176 phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	4 mo2–11 · 176 studies	4 mo2–9 · 158 studies	—
Phase 1/2	29 mo18–… · 20 studies	—	—
Phase 2	17 mo10–31 · 165 studies	14 mo7–20 · 118 studies	39 mo20–63 · 47 studies
Phase 3	23 mo14–44 · 141 studies	20 mo13–36 · 108 studies	40 mo26–56 · 33 studies
Phase 4	19 mo12–40 · 157 studies	15 mo9–22 · 71 studies	29 mo14–50 · 86 studies
Interventional, no phase	22 mo10–39 · 1,181 studies	21 mo10–35 · 87 studies	22 mo10–41 · 1,094 studies
Observational	26 mo14–58 · 586 studies	21 mo14–37 · 120 studies	29 mo15–64 · 466 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out